CLSD Clearside Corp Expected net earnings per share growth this year

Official company branding of Clearside Corp (CLSD)

Clearside Biomedical (CLSD) relies on a unique suprachoroidal drug delivery technology that ensures current stability. In the long term, a diversified retinopathy treatment pipeline in partnership with pharma behemoths minimizes risks. Full capacity utilization of precision molding confirms manufacturing readiness. The year-over-year EPS percentage change visualizes this trend, where 34.30 determines the current status of the parameter.

Clearside Biomedical Inc (CLSD): Earnings per share growth in current year from 07/04/2022 to 12/13/2025

Financial and market metric breakdowns for Clearside Biomedical (CLSD)

- stock value and consensus price forecast:
Market Price Clearside Biomedical Inc|CLSD - Price Target Chart
- market capitalization data:
Market Capitalization Clearside Corp|CLSD - Enterprise Value
- shareholders' equity book value data:
Accounting Value per Share Clearside Biomedical|CLSD - Company Book Value|Market Value to Book Value Ratio clearsidebio.com|CLSD - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital Clearside Biomedical|CLSD - Long-Term Debt to Capital|Short-Term Debt to Capital clearsidebio.com|CLSD - Company Debts|Debt to Net Assets Ratio Clearside Corp|CLSD - Company Long-Term Debt|Short-Term Debt Volume Clearside Biomedical|Interim Coverage Ratio clearsidebio.com
- net income and valuation ratios data:
CLSD - Net Profit|Net Profit Forecast Clearside Biomedical|CLSD - P/E Multiple|Projected Price to Earnings Ratio Clearside Corp|CLSD - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Clearside Corp|CLSD - Operating profit EBITDA|Earnings per share for the last twelve months Clearside Biomedical|CLSD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months clearsidebio.com|CLSD - Earnings per share growth in current year|Expected net earnings per share growth next year Clearside Biomedical
Basic company analysis:Clearside Biomedical Inc (CLSD)
Signature product of Clearside Biomedical

Professional managers utilize fundamental filters to evaluate capital efficiency. This indicator measures the percentage deviation of current net income per share compared to the same period last year. For Clearside Biomedical (CLSD), this trend reflects the commercialization of their unique suprachoroidal injection technology. Steady growth confirms the successful expansion of this innovative drug delivery method. By analyzing the annual growth rate of net income per share, an investor determines the risk of overpayment.

Main competitors

Earnings per share growth rate in current year Alcon Inc (ALC)|Earnings per share growth in current year Bausch + Lomb Corp|Glaukos Medical (GKOS) - Expected net earnings per share growth this year|Earnings growth in current year APLS|Net earnings per share growth this year Belite Bio, Inc. BLTE|Earnings per share growth in current year Ocular Therapeutix, Inc. OCUL|Harrow Inc - Earnings per share growth in current year|Viridian Pharma - Earnings growth in current year|Earnings per share growth rate in current year LENZ Corp|OCS: Earnings growth in current year|eyepointpharma.com (EYPT) - Earnings growth in current year|Earnings per share growth in current year Kodiak Sciences|ALDX: Earnings per share increase in current year|Earnings per share growth in current year KALA BIO, Inc. (KALA)|Expected net earnings per share growth this year opusgtx.com|Earnings growth in current year OKYO (OKYO Pharma)|Expected net earnings per share growth this year Adverum Biotechnologies Inc. (ADVM)|Outlook Therapeutics, Inc. - Earnings growth in current year|NBY (NovaBay Pharmaceuticals) - Earnings per share growth this year|KPRX: Earnings growth in current year|Earnings per share growth rate in current year Alimera Sciences, Inc. (ALIM)|Net earnings per share growth this year EYEN|GHSI: Earnings per share increase in current year|Earnings growth in current year OCUP|Earnings per share growth in current year OPT (Opthea Ltd)